Desferrioxamine B

Desferrioxamine B (also called deferoxamine) is a chemical compound that strongly binds iron, pulling it out of solution or away from surfaces. In asbestos research, scientists use it as a laboratory tool to strip iron from the surface of asbestos fibers so they can study how iron drives the fiber's toxic effects. It is also an FDA-approved medication used to treat iron overload in patients with conditions like thalassemia.

Origin

Desferrioxamine B is a siderophore, an iron-scavenging molecule, originally isolated in the 1960s from the bacterium Streptomyces pilosus by researchers at Ciba (now Novartis). It was developed clinically as Desferal for treating iron overload, and was later adopted by toxicologists studying oxidative damage caused by mineral fibers.

Significance in Asbestos Context

Iron on the surface of asbestos fibers (especially amphiboles like crocidolite and amosite, which are iron-rich by composition) generates reactive oxygen species that damage DNA and drive mesothelioma and lung cancer. In landmark experiments, treating fibers with desferrioxamine B reduced their ability to cause DNA strand breaks and free-radical damage, providing some of the strongest evidence that iron-catalyzed oxidative stress is a key mechanism of asbestos carcinogenicity. For patients, this matters because it underlies expert testimony explaining why amphibole fibers (and contaminated talc containing them) are biologically potent even at low doses, and why arguments that a particular fiber type is harmless are scientifically untenable.

Example Sentence

The plaintiff's expert cited desferrioxamine B experiments to explain to the jury how iron on the surface of amphibole fibers generates the free radicals that ultimately caused the patient's mesothelioma.

Related Terms

Reactive Oxygen Species, Crocidolite, Amphibole Asbestos, Iron-Catalyzed Oxidation, Free Radical Generation, Fenton Reaction

Notes

• If your case involves amphibole exposure (crocidolite, amosite, tremolite) or asbestos-contaminated talc, ask whether your legal team's scientific experts address iron-mediated oxidative damage as a mechanism of causation.
• Mechanistic evidence like the desferrioxamine B studies is often used to rebut defense arguments that low-dose or short-duration exposures could not have caused disease. Preserve any records showing fiber type and exposure context.
• This compound is not a treatment for mesothelioma or asbestosis; do not confuse its laboratory use in asbestos research with a clinical therapy for asbestos disease.